2013, Number 1
<< Back Next >>
Ann Hepatol 2013; 12 (1)
Hepatitis C virus infection in patients with primary biliary cirrhosis
Hsuan-Wei C, Hsin-Hung H, Ching-Huang L, Wei-En C, Yu-Lueng S, Wei-Kuo C, Tsai-Yuan H, Heng-Cheng C
Language: English
References: 33
Page: 78-84
PDF size: 98.30 Kb.
ABSTRACT
Background and aim. The aim of this study is to evaluate the role of hepatitis C virus (HCV) infection in patients
with primary biliary cirrhosis (PBC).
Material and methods. On the basis of a retrospective review of
medical records, all patients consecutively diagnosed with PBC or HCV infection between 1999 and 2011
and who had a regular follow-up of at least 3 years were included in the study. Clinical characteristics, especially
the severity of cirrhosis, were analyzed in PBC patients with HCV infection (PBC-HCV), PBC patients
without HCV infection (PBC-only), and patients with only HCV infection (HCV-only).
Results. A total
of 76 patients with PBC, including 9 patients with HCV infection, were analyzed. Of the PBC-HCV patients,
7 (7/9, 77.8%) were women with a mean age of 55.11 ± 14.29 years. Age- and sex-matched PBC-only patients
(n = 36) and HCV-only patients (n = 36) were used as control groups. In comparison to the PBC-only controls,
PBC-HCV patients had a greater severity of cirrhosis based on Child-Pugh (p = 0.019) and Model for
End-Stage Liver Disease (MELD) (p = 0.01) scores. However, no significant difference in the severity of
cirrhosis was found between the PBC-HCV and HCV-only control patients (p = 0.94 in Child-Pugh
scores; p = 0.64 in MELD scores).
Conclusions. In PBC patients with concomitant HCV infection, aggressive management
may be warranted in view of the associated more severe liver cirrhosis.
REFERENCES
Kaplan MM, Gershwin ME. Primary biliary cirrhosis. N Engl J Med 2006; 353: 1261-73.
Myers RP, Shaheen AA, Fong A, Burak KW, Wan A, Swain MG, Hilsden RJ, et al. Epidemiology and natural history of primary biliary cirrhosis in a Canadian health region: a population- based study. Hepatology 2009; 50: 1884.
Kumagi T, Heathcote EJ. Primary biliary cirrhosis. Orphanet J Rare Dis 2008; 3: 1.
Poupon RE, Lindor KD, Parés A, Chazouilleres O, Poupon R, Heathcote EJ. Combined analysis of the effect of treatment with ursodeoxycholic acid on histologic progression in primary biliary cirrhosis. J Hepatol 2003; 39: 12-16.
Davis GL, Albright JE, Cook SF, Rosenberg DM. Projecting future complications of chronic hepatitis C in the United- States. Liver Transpl 2003; 9: 331-8.
Haddad J, Deny P, Munz-Gotheil C, Ambrosini JC, Trinchet JC, Pateron D, Mal F, et al. Lymphocytic sialadenitis of Sjögren’s syndrome associated with chronic hepatitis C virus liver disease. Lancet 1992; 339: 321-3.
Marcellin P, Pouteau M, Benhamou JP. Hepatitis C virus infection, alpha interferon therapy and thyroid dysfunction. J Hepatol 1995; 22: 364-9.
Lunel F, Cacoub P. Treatment of autoimmune and extrahepatic manifestations of hepatitis C virus infection. J Hepatol 1999; 31: 210-6.
Floreani A, Baragiotta A, Leone MG, Baldo V, Naccarato R. Primary biliary cirrhosis and hepatitis C virus infection. Am J Gastroenterol 2003; 98: 2757-62.
Wiesner R, Edwards E, Freeman R, Harper A, Kim R, Kamath P, Kremers W, et al. Model for end-stage liver disease (MELD) and allocation of donor livers. Gastroenterology 2003; 124: 91-6.
Housset C, Hirschauer C, Degos F. False positive anti-HCV in biliary cirrhosis. Lancet 1991; 114: 252 (Letter).
Fusconi M, Lenzi M, Ballardini G, Miniero R, Cassani F, Zauli D, Bianchi FB. Anti-HCV testing in autoimmune hepatitis and primary biliary cirrhosis. Lancet 1990; 336: 823.
Imada J, Hoshino H, Nishimura D, Morita K, Yoshida N, Katada N, Sano H, et al. Case report: multiple cancers: hepatocellular carcinoma and adenocarcinomas of the common bile duct and the gall-bladder in a woman with primary biliary cirrhosis. J Gastroenterol Hepatol 1996; 11: 546-50.
Hoso M, Nakanuma Y, Kawano M, Oda K, Tsuneyama K, van de water J, Gershiwin ME. Granulomatous cholangitis in chronic hepatitis C: a new diagnostic problem in liver pathology. Pathol Int 1996; 46: 301-5.
Mouelhi L, Chaieb M, Sfar I, Debbeche R, Trabelsi S, Gorgi Y, Najjar T. Chronic viral C hepatitis associated with primary biliary cirrhosis. Report of two cases. Rev Med Interne 2009; 30: 537-9.
Ramos-Casals M, Pares A, Jara LJ, Solans R, Viñas O, Vázquez P, Sánchez-Tapias, et al; HISPAMEC Study Group. Antimitochondrial antibodies in patients with chronic hepatitis C virus infection: description of 18 cases and review of the literature. J Viral Hepat 2005; 12: 648-54.
Sung JL. Prevention of hepatitis B and C virus infection for prevention of cirrhosis and hepatocellular carcinoma. J Gastroenterol Hepatol 1997; 12: S370-S376.
Wang JT, Wang TH, Sheu JC, Tsai SJ, Hsieh YS, Lin DT, Wang CY, et al. 1993. Hepatitis C virus infection in volunteer blood donors in Taiwan. Evaluation by hepatitis C antibody assays and the polymerase chain reaction. Arch Pathol Lab Med 1993; 117: 152-6.
Nakamura M, Yasunami M, Kondo H, Horie H, Aiba Y, Komori A, Migita K, et al; PBC Study Group in NHOSLJ. Analysis of HLA-DRB1 polymorphisms in Japanese patients with primary biliary cirrhosis (PBC): The HLA-DRB1 polymorphism determines the relative risk of antinuclear antibodies for disease progression in PBC. Hepatol Res 2010; 40: 494- 504.
Gershwin ME, Selmi C, Worman HJ, Gold EB, Watnik M, Utts J, Lindor KD, et al. Risk factors and comorbidities in primary biliary cirrhosis: a controlled interview based study of 1032 patients. Hepatology 2005; 42: 1194-202.
Ala A, Stanca CM, Bu-Ghanim M, Ahmado I, Branch AD, Schiano TD, Odin JA, et al. Increased prevalence of primary biliary cirrhosis near superfund toxic waste sites. Hepatology 2006; 43: 525-31.
Ishibashi H, Komori A, Shimoda S, Ambrosini YM, Gershwin ME, Nakamura M. Risk factors and prediction of long-term outcome in primary biliary cirrhosis. Intern Med 2011; 50: 1-10.
Cavazza A, Caballería L, Floreani A, Farinati F, Bruguera M, Caroli D, Parés A. Incidence, Risk Factors, and Survival of Hepatocellular Carcinoma in Primary Biliary Cirrhosis: Comparative Analysis from Two Centers. Hepatology 2009; 50: 1162-8.
Macaron C, Hanouneh IA, Zein NN. Incidence, Risk Factors, and Survival of Hepatocellular Carcinoma in Primary Biliary Cirrhosis. Hepatology 2010; 52: 2239; author reply 2239-40.
Michel F, Toussirot E, Wendling D. Primary biliary cirrhosis and systemic lupus erythematosus. A new case report. Rev Rhum Engl Ed 1998; 65: 504-7.
Shizuma T, Kuroda H. A case of primary biliary cirrhosis which developed eight years after diagnosis of systemic lupus erythematosus. Intern Med 2011; 50: 321-4.
Watt EF, James OF, Jones DE. Patterns of autoimmunity in primary biliary cirrhosis patients and their families: a population-based cohort study. QJM 2004; 97: 397-406.
Fried MW, Shiffman ML, Reddy KR, Smith C, Marinos G, Gonçales FL Jr, Häussinger D, et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 2002; 26: 975-82.
Yoshikawa M, Mimura M, Shiroi A, Kojima H, Fukui H, Sugimoto Y, Mochi T. Primary biliary cirrhosis exacerbated by a course of acute hepatitis C and subsequent interferon therapy. Am J Gastroenterol 2000; 95: 2396-7.
Maeda T, Onishi S, Miura T, Iwamura S, Tomita A, Saibara T, Yamamoto Y. Exacerbation of primary biliary cirrhosis during interferon-alpha 2b therapy for chronic active hepatitis C. Dig Dis Sci 1995; 40: 1226-30.
D’Amico E, Paroli M, Fratelli V, Palazzi C, Barnaba V, Callea F, Consoli G. Primary biliary cirrhosis induced by interferon- alpha therapy for hepatitis C virus infection. Dig Dis Sci 1995; 40: 2113-6.
Lok AS, Gardiner DF, Lawitz E, Martorell C, Everson GT, Ghalib R, Reindollar R, et al. Preliminary study of two antiviral agents for hepatitis C genotype 1. N Engl J Med 2012; 366: 216-24.
Chung RT. A Watershed Moment in the Treatment of Hepatitis C. N Engl J Med 2012; 366: 273-5.
Full text